IDDI, Biostatistical and eClinical Services for Clinical Trials

TRIAL DESIGN - RANDOMIZATION - DATA MANAGEMENT - BIOSTATISTICS
Twitter icon
Facebook icon
LinkedIn icon
Google+ icon
YouTube icon
RSS icon

Secondary menu

Home > Content > History

History

1991

 

BRUSSELS, BELGIUM

The International Institute for Drug Development (ID²) was established in Brussels (Belgium) in 1991 by Marc Buyse  ScD.

 

1996

 

 

PARIS, FRANCE 

The company expanded its client base in France and opened an office in Paris to ensure proximity to its French clients.

 
 

2001

 

 

CAMBRIDGE, MA, USA

The company was renamed IDDI, International Drug Development Institute.

An office was opened in Cambridge, Massachusetts, to offer advanced Web-based services for clinical trials supported by a dedicated help desk to cover the American time zones. Business development and Finance still operate out of Cambridge, MA to serve IDDI American clients.

 

2004

 

 

Closed Paris office and consolidated European team in Belgium.

 

 

2006

 

 

LOUVAIN-LA-NEUVE, BELGIUM

Moved headquarter to Louvain-la-Neuve.

 

2011

 

 

HOUSTON, TX, USA

IDDI opened a new office in Houston Texas. Operational team in the US.

 

2012

 

 

CLUEPOINTS

Creation of a new branch, CluePoints, dedicated to Central Statistical Monitoring applied to clinical trials.

 

2013

 

 

NEW LOGO AND STRATEGY

Revamp of IDDI Logo and strategy based on the three pillars of the company: PEOPLE, METHODOLOGY and TECHNOLOGY.

 

2014

 

 

RALEIGH, NS, USA

IDDI opens a new office in Raleigh in October 2014 and provides Data Management, Biostatistics and Project Management staff to serve US based clients.

 
2016  

IDDI 25 YEAR ANNIVERSARY 

 

Today

 

 

With 25 years of experience, IDDI is a valuable partner in the design, conduct and analysis of clinical trials through optimal design, innovative statistical methodology and state-of-the-art integrated web systems that help achieve time savings and cost-effective clinical trial processes. To ensure its continuous growth, the company is considering a potential acquisition in the US.